File Download
There are no files associated with this item.
Supplementary
- Citations:
- Appears in Collections:
Article: Effect of 13-cis-retinoic acid and α-interferon on transforming growth factor in patients with rising prostate-specific antigen
Title | Effect of 13-cis-retinoic acid and α-interferon on transforming growth factor in patients with rising prostate-specific antigen |
---|---|
Authors | |
Issue Date | 1997 |
Citation | Clinical Cancer Research, 1997, v. 3, n. 11, p. 1999-2004 How to Cite? |
Abstract | The objective of this study was to test the hypothesis that 13-cis- retinoic acid (CRA) and α-interferon (IFN-α) have antitumor activity in patients with early recurrence of prostate cancer measured by rising prostate-specific antigen (PSA) after local therapy, and that this activity is associated with the increase of plasma transforming growth factor β1 (TGF-β1). Thirty patients with a PSA > 7 ng/ml that increased >0.4 ng/ml/month after initial radiation therapy or a PSA > 2.0 ng/ml after prostatectomy were treated with 1 mg/kg/day of CRA and 3 million units of IFN-α administered three times per week. Patients were followed clinically with serum measurements of PSA and assessment of toxicity. Biological activity of CRA and IFN-α was assessed by the measurement of plasma TGF- β1. Twenty-six percent of patients had a partial (50% decrease maintained for 1 month) or minimal (<50% decrease maintained for 1 month) biochemical response of PSA, with a median decrease of 23% (11-55%) at 3 months. Plasma TGF-β1 levels increased with CRA and IFN-α therapy and correlated with a decrease in PSA; patients with a decrease in PSA had a 151% increase in TGF- β1 compared to 27% in patients without a decrease in PSA (P = 0.04). CRA and IFN-α can produce transient reduction or stabilization of PSA. The measurement of plasma TGF-β1 at 1 month of therapy correlates with changes in PSA and may represent a useful marker for the biological effect of these agents; further analysis in larger numbers of patients and methods to optimize these effects should be explored. |
Persistent Identifier | http://hdl.handle.net/10722/266758 |
ISSN | 2023 Impact Factor: 10.0 2023 SCImago Journal Rankings: 4.623 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | DiPaola, Robert S. | - |
dc.contributor.author | Weiss, Robert E. | - |
dc.contributor.author | Cummings, Kenneth B. | - |
dc.contributor.author | Kong, Feng Ming | - |
dc.contributor.author | Jirtle, Randy L. | - |
dc.contributor.author | Anscher, Mitchell | - |
dc.contributor.author | Gallo, Jose | - |
dc.contributor.author | Goodin, Susan | - |
dc.contributor.author | Thompson, Sharon | - |
dc.contributor.author | Rasheed, Zeeshan | - |
dc.contributor.author | Aisner, Joseph | - |
dc.contributor.author | Todd, Mary B. | - |
dc.date.accessioned | 2019-01-31T07:19:30Z | - |
dc.date.available | 2019-01-31T07:19:30Z | - |
dc.date.issued | 1997 | - |
dc.identifier.citation | Clinical Cancer Research, 1997, v. 3, n. 11, p. 1999-2004 | - |
dc.identifier.issn | 1078-0432 | - |
dc.identifier.uri | http://hdl.handle.net/10722/266758 | - |
dc.description.abstract | The objective of this study was to test the hypothesis that 13-cis- retinoic acid (CRA) and α-interferon (IFN-α) have antitumor activity in patients with early recurrence of prostate cancer measured by rising prostate-specific antigen (PSA) after local therapy, and that this activity is associated with the increase of plasma transforming growth factor β1 (TGF-β1). Thirty patients with a PSA > 7 ng/ml that increased >0.4 ng/ml/month after initial radiation therapy or a PSA > 2.0 ng/ml after prostatectomy were treated with 1 mg/kg/day of CRA and 3 million units of IFN-α administered three times per week. Patients were followed clinically with serum measurements of PSA and assessment of toxicity. Biological activity of CRA and IFN-α was assessed by the measurement of plasma TGF- β1. Twenty-six percent of patients had a partial (50% decrease maintained for 1 month) or minimal (<50% decrease maintained for 1 month) biochemical response of PSA, with a median decrease of 23% (11-55%) at 3 months. Plasma TGF-β1 levels increased with CRA and IFN-α therapy and correlated with a decrease in PSA; patients with a decrease in PSA had a 151% increase in TGF- β1 compared to 27% in patients without a decrease in PSA (P = 0.04). CRA and IFN-α can produce transient reduction or stabilization of PSA. The measurement of plasma TGF-β1 at 1 month of therapy correlates with changes in PSA and may represent a useful marker for the biological effect of these agents; further analysis in larger numbers of patients and methods to optimize these effects should be explored. | - |
dc.language | eng | - |
dc.relation.ispartof | Clinical Cancer Research | - |
dc.title | Effect of 13-cis-retinoic acid and α-interferon on transforming growth factor in patients with rising prostate-specific antigen | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.pmid | 9815590 | - |
dc.identifier.scopus | eid_2-s2.0-0030665439 | - |
dc.identifier.volume | 3 | - |
dc.identifier.issue | 11 | - |
dc.identifier.spage | 1999 | - |
dc.identifier.epage | 2004 | - |
dc.identifier.issnl | 1078-0432 | - |